The day in pharma, read in minutes.
NewsInfex Therapeutics Reports Phase IIa Signal in Bronchiectasis
Infex Therapeutics reports Phase IIa RESP-X data showing annualised exacerbation rates drop from 3.4 to 1.2 in Pa-colonised NCFB patients.
Novartis HARBOR Phase III Trial Misses Primary Endpoint
Cormica Opens Medical Device Chemistry Lab in Bradford
HRV Pharma Commits Rs. 150 Crore to Build API Capacity
Sanofi Signs Three-Year Partnership with Tricog to Scale AI Cardiac Diagnostics
Latest news
11 storiesPfizer Discontinues Minipress XL Following Global Manufacturing Cessation Decision
Pfizer discontinues Minipress XL globally after a manufacturing cessation directive, triggering regulatory notification and supply continuity obligations across active markets.
Novo Nordisk Achieves Primary Endpoint in STEP Young Phase 3 Trial for Pediatric Semaglutide Indication
Novo Nordisk's STEP Young phase 3 trial met its primary endpoint, with 40.4% of semaglutide-treated children no longer classified as obese at week 68.
AstraZeneca Wins FDA Nod After SERENA-6 Cuts Progression Risk 56%
AstraZeneca secures FDA accelerated approval for its breast cancer drug based on SERENA-6 trial data showing a 56% reduction in progression risk.
Fosun Pharma Secures HK$1B H-Share Buyback via Gland Stake Sale
Fosun Pharma funds a HK$1B H-share buyback by selling ~6% of Gland Pharma for US$294M, raising questions for Gland's CDMO partners.
Indian Immunologicals Disputes Abhayrab Findings, Submits Records
Indian Immunologicals denies producing substandard Abhayrab vials found in Delhi, submitting full batch and distribution records to CDSCO on 14 August 2026.
Rezubio Gains FDA, NMPA IND Clearances for Inhaled RZ-520
Rezubio completes first-cohort dosing of RZ-520 after securing parallel FDA and NMPA IND clearances for its inhaled chronic respiratory disease candidate.
Data Integrity, Not Scale, Is India's Real Competitive Advantage - Chakravarthi AVPS on India's Pharma Leadership at GPACTS 2026
At GPACTS 2026, Chakravarthi AVPS declared data integrity, not scale, as India's pharma competitive advantage amid FDA, EMA scrutiny and AI-driven manufacturing.
FDA Issues Emergency Guidance After Neonatal PN Supply Shutdowns
FDA issues immediate compounding guidance after two outsourcing facility shutdowns create a neonatal parenteral nutrition supply gap.
Novartis Pelacarsen Fails Phase III Lp(a) Trial
Novartis pelacarsen fails Lp(a)HORIZON Phase III primary endpoint in 8,323 patients, raising ASO manufacturing and Ionis collaboration capacity questions.
AstraZeneca Wins FDA Approval for Camizestrant in Breast Cancer
FDA grants AstraZeneca accelerated approval for camizestrant in ESR1-mutation breast cancer, the first ctDNA resistance-guided oncology approval.
AstraZeneca Wins FDA Accelerated Nod for Camizestrant
FDA grants accelerated approval to AstraZeneca's camizestrant with a CDK4/6 inhibitor for ESR1-mutated HR+/HER2- metastatic breast cancer, tied to Guardant360 CDx companion diagnostic.
Worth your time this week
FDA Flags ZUBB Supplement for Hidden Sildenafil
Tarsus Acquires Alkeus, Adds Phase 3 Stargardt Drug
Teva Gains Investment-Grade Status from All Three Major Rating Agencies After S&P Upgrade
